hMaxi-K gene therapy

Drug Profile

hMaxi-K gene therapy

Alternative Names: hMaxi-K - Ion Channel Innovations

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ion Channel Innovations LLC
  • Developer Ion Channel Innovations
  • Class Erectile dysfunction therapies; Gene therapies; Urologics
  • Mechanism of Action Calcium-activated potassium channel openers; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Erectile dysfunction
  • No development reported Overactive bladder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Erectile-dysfunction in USA (Intracavernous)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Overactive bladder in USA (Intravesicular)
  • 01 Sep 2013 Ion Channel Innovations initiates enrolment in a phase I trial for Overactive bladder in USA (NCT01870037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top